Download the Toolkit from T1International. Thanks to funding fromBeyond Type 1, our friends at T1International have created a resource for people around the world who want to advocate for better access to insulin, diabetes supplies, care or education. Chapters, with associated international case-studies, include: Understand The Issue Plan Your Action Take Action Evaluate & Celebrate […]
Category: Uncategorized
In this episode of TuDiabetes Talks: Advocacy Edition, Mandy Jones interviews Elizabeth Rowley, the founder of T1International. We discuss thinking globally, but acting locally as well as maintaining advocate stamina when so many PWDsneed support getting insulin during crises (ie. Syria, Venezuela). T1International is a registered charitable incorporated organisation (CIO) in England and Wales. Their […]
Former host of diabeticfeed, a podcast about diabetes and diabetes research. Former dlife.com contributor. Former non-profit executive. Now? Plotting. Author of ThePerfectD T1 since 1983. Wife since 2007. Mom since 2011. Perfect since never.
Without insulin, many people with diabetes (PWDs) would die. Its not a luxury item; its a necessity. Endocrinologist Dr. Silvio Inzucchi estimates in someone with 0% insulin production, theyll begin to fall ill within 12-24 hours after last insulin injection, depending on its duration of effectand mortal outcomes would likely occur within days to perhaps […]
From:https://t1dexchange.org/pages/t1d-exchange-presents-data-on-new-form-of-glucagon-rescue-treatment-for-severe-hypoglycemia/ At global ATTD conference, scientists also share new insight on severe hypoglycemia in older adults with type 1 diabetes an emerging challenge as patients live longer PARIS, February 18, 2015 Research fromT1D Exchangescientists presented at theAdvanced Technologies & Treatments for Diabetes (ATTD)international conference heralds a new approach to glucagon delivery for rescue treatment for […]
From:http://www.medpagetoday.com/Endocrinology/Diabetes/49849 The FDA has approved the first combination pill of an SGLT2 inhibitor and a DPP-4 inhibitor, to be marketed as Glyxambi, drugmakers Eli Lilly and Boehringer Ingelheim announced. The combination of 10 or 25 mg of empagliflozin and 5 mg of linagliptin is approved as an adjunct to diet and exercise to improve glycemic […]